71. 依據 2018 HCC EASL Clinical Practice Guidelines，Liver transplantation 的敘述下列何者錯誤？
(1) Liver transplantation is recommended as the first-line option for HCC within Milan criteria but unsuitable for resection
(2) Consensus on expanded criteria for liver transplantation in HCC has not been reached
(3) UCSF criteria include single nodule ≤5 cm or 2–3 nodules ≤3 cm and total tumor diameter ≤6.5 cm
(4) Total tumor volume (TTV) criteria + alpha-fetoprotein (AFP) defined as TTV＜115 cm3 and AFP ＜400 ng/ml
(A) (3)
(B) (2)
(C) (2)＋(3)
(D) (3)＋(4)

(E) (2)＋(4)

67. 關於 Liver Imaging Reporting and Data System(LI-RADS)system，下列敘述何者錯誤？(1) LI-RADS 1 and LI-RADS2 indicate definitely and probably benign(2) LI-RADS 3 indicates a low probability of HCC(3) “a small nodular area of CT/MR arterial phase hyperenhancement, which is not present on other phases” is classified as LI-RADS 2(4) “a ≥2-cm encapsulated lesion with CT/MR arterial phase hyperenhancement, but without “washout” is classified as LI-RADS 4(5) “a ≥2-cm lesion that enhances to the same degree as liver in the CT/MR arterial phase, but enhances less (i.e., is hypoenhanced) in the postarterial phases” is classified as LI-RADS 3(A) (1)＋(4)(B) (2)＋(3)(C) (3)(D) (2)＋(3)＋(5)(E) (3)＋(5)

68. GALAD model 可以運用在 HCC 診斷，下列何者不屬於 GALAD model 的組成項目？(A) Platelet count(B) AFP-L3%(C) DCP(protein induced by vitamin K absence/antagonist-II)(D) Sex(E) Age

69. 依據 2018 EASL Clinical Practice Guidelines 關於 BCLC 的敘述，下列何者錯誤？(1) Very early HCC (BCLC stage 0) is defined as the presence of a single tumor＜2 cm in diameter without vascular invasion/satellites in patients with good health status (ECOG-0) and well-preserved liver function (Child-Pugh Aclass)(2) Early HCC (BCLC stage A) is defined in patients presenting with single tumors ＞2 cm or three nodules ＜3 cm in diameter, ECOG-0 and preservedliver function(3) Large solitary HCC beyond 5 cm should be classified as BCLC B(4) Among BCLC B, Child-Pugh B patients with refractory ascites and hepatic encephalopathy, liver transplantation should not be considered(A) (3)(B) (4)(C) (1)＋(3)(D) (3)＋(4)(E) (2)＋(3)

70. 依據 2018 HCC EASL Clinical Practice Guidelines，下列何者錯誤？(1) Liver resection is recommended for single HCC of any size and in particular for tumors ＞2 cm, when hepatic function is preserved, and sufficientremnant liver volume is maintained(2) Assessment of response in HCC should be based on RECIST1.1 for loco-regional therapies(3) For systemic therapies both mRECIST and RECIST1.1 are recommended to assess the response(4) HCC with tumor-related portal vein thrombosis (PVTT) can be graded as PV1 (segmentary), PV2 (secondary order branch), PV3 (first order branch),and PV4 (main trunk/contralateral branch)(5) Liver resection can be considered for PV1/2 extension of HCC(A) (3)(B) (2)(C) (2)＋(3)(D) (3)＋(4)(E) (2)＋(5)

72. 依據 2018 HCC EASL Clinical Practice Guidelines，Local ablation 的敘述下列何者正確？(1) RFA is the standard of care for patients with BCLC 0 and A tumors not suitable for surgery(2) For BCLC-0, RFA in favorable locations can be adopted as first-line therapy(3) Ethanol injection is an option in some cases where RFA is not technically feasible, especially in tumors ＜2 cm(4) For sub-capsular HCCs, the technical success and the risk of complications should be considered when applying RFA(5) Tumor location has highly important consequences on the choice between RFA or surgery(A) (1)＋(2)(B) (1)＋(2)＋(3)(C) (1)＋(2)＋(3)＋(4)(D) (1)＋(2)＋(3)＋(4)＋(5)(E) (1)＋(2)＋(4)

73. 依據 2018 HCC EASL Clinical Practice Guidelines，TACE 的敘述下列何者正確？(1) The indication for TACE should consider tumour burden, underlying liver disease, and performance status(2) Inadequate hepatic function, such as serum bilirubin ＞2 mg/dl, and a tumor burden ＞50% of total liver volume, increase the risk of hepaticdecompensation after TACE(3) Segmental or sub-segmental portal vein tumor invasions are absolute contraindications for TACE(4) Patients with biliary-enteric anastomosis or biliary stent are at higher risk of hepatic abscess by TACE(A) (1)＋(2)(B) (1)＋(2)＋(3)(C) (2)＋(3)＋(4)(D) (1)＋(2)＋(3)＋(4)(E) (1)＋(2)＋(4)

74. 關於 HCC systemic therapy 的敘述下列何者正確？(1) Systemic chemotherapy with doxorubicin or FOLFOX did not demonstrate survival benefits(2) Lenvatinib targets VEGFR1-3; fibroblast growth factor receptor (FGFR1-4);platelet-derived growth factor receptor α, RET, and KIT(3) Cabozantinib is a MET, VEGFR2 and RET inhibitor approved for thyroid,renal cancer and HCC(4) Ramucirumab is a monoclonal antibody targeting VEGFR 1-3(5) Progression-free survival is a composite endpoint that includes two types of variables: death and evidence of radiological progression(A) (1)＋(2)(B) (1)＋(2)＋(3)(C) (2)＋(3)＋(4)(D) (1)＋(2)＋(3)＋(5)(E) (1)＋(2)＋(3)＋(4)＋(5)

75. 依據 2018 AASLD Guidelines for the Treatment of Hepatocellular Carcinoma，下列何者敘述錯誤？(1) The AASLD suggests surveillance using ultrasound (US) and alpha-fetoprotein (AFP) every 6 months(2) The AASLD recommends diagnostic evaluation for HCC with either multiphasic CT or multiphasic MRI because of similar diagnosticperformance characteristics(3) The AASLD suggests that adults with Child-Pugh class A cirrhosis and resectable T1 or T2 HCC undergo resection over radiofrequency ablation(4) The AASLD does not recommend one form of liver-directed therapy over another for the purposes of bridging to liver transplantation for patientswithin Milan criteria(A) (1)(B) (2)(C) (3)(D) (4)(E) (1)＋(3)

76. HCC systemic therapy 在第三期臨床試驗中，下列何者未納入 main portal vein invasion 進入試驗？(1) IMbrave 150(2) REFLECT(3) KEYNOTE 240(4) RESORCE(A) (1)＋(2)(B) (2)＋(3)(C) (1)＋(2)＋(3)(D) (2)(E) (1)＋(3)

77. 關於 HCC systemic therapy，依據 phase 3 clinical trials 的結果，下列敘述何者正確？(1) Atezolizumab + Bevacizumab 在一線 systemic therapy，objective response rate (ORR) ＞25%(2) Lenvatinib 在一線 systemic therapy，objective response rate (ORR) ＞20%(3) Sorafenib 在一線 systemic therapy，最好的 median overall survival 可以超過 14 個月(4) Median progression-free survival (PFS)，lenvatinib 不輸於 Atezolizumab +Bevacizumab(A) (1)(B) (1)＋(2)(C) (1)＋(2)＋(3)(D) (1)＋(2)＋(3)＋(4)(E) (1)＋(3)